CTMX NASDAQ
CytomX Therapeutics, Inc.
1W: -4.7%
1M: -17.4%
3M: -30.8%
YTD: -47.5%
1Y: -32.4%
3Y: +66.4%
5Y: -55.4%
$2.31
+0.09 (+3.82%)
After Hours: $2.38 (+0.07, +3.03%)
Weekly Expected Move ±9.0%
$2
$2
$2
$3
$3
Credit Risk of going bust: lower than 54% of companies Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.8%), CytomX Therapeutics, Inc. would be worth roughly what it owes.
Total debt $5.7M against a stock market value of $484.8M.
Distance to default 5.54 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.6M (short-term plus half of long-term), stock volatility 83.8%; Altman Z'' 1.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.8%), CytomX Therapeutics, Inc. would be worth roughly what it owes.
Total debt $5.7M against a stock market value of $484.8M.
Distance to default 5.54 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.6M (short-term plus half of long-term), stock volatility 83.8%; Altman Z'' 1.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (68)
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Has Average Price Target of $11.90 According to Brokerages
CytomX Therapeutics (NASDAQ:CTMX) Reaches New 1-Year Low – Should You Sell?
CytomX Therapeutics (NASDAQ:CTMX) Sets New 52-Week Low – Here’s Why
AWM Investment Company Inc. Acquires Shares of 150,000 CytomX Therapeutics, Inc. $CTMX
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
ADAR1 Capital Management LLC Sells 872,579 Shares of CytomX Therapeutics, Inc. $CTMX
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
CytomX (CTMX) Q4 2025 Earnings Transcript
Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
CytomX (CTMX) Q1 2026 Earnings Transcript
CytomX expects cash runway to at least the second half of 2028 as Varseta-M targets a first half of 2027 registrational study
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX GAAP EPS of -$0.10 beats by $0.03, revenue of $10.26M beats by $5.58M
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
Stock Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 4.9% – Should You Buy?
Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) CEO Sells $763,780.98 in Stock
12 Health Care Stocks Moving In Thursday's Intraday Session
CytomX Therapeutics (NASDAQ:CTMX) Sees Large Volume Increase After Analyst Upgrade
HC Wainwright Has Pessimistic Outlook of CTMX Q1 Earnings
Why Is CytomX Therapeutics Stock Falling On Wednesday?
CytomX Therapeutics prices $250M public offering at $5.30 per share
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Down 4.2% After Earnings Miss
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
CytomX Therapeutics launches $250M public offering
12 Health Care Stocks Moving In Monday's Intraday Session
Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally
J.P. Morgan outlines CRM options play for uncertain Iran war outcome
CytomX outlines registrational trial plans for Varseta-M in third-line colorectal cancer with initial study start in 2027
Crude Oil Down 4%; Dollar Tree Earnings Top Views
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
12 Health Care Stocks Moving In Monday's Pre-Market Session
Earnings Scheduled For March 16, 2026
CytomX GAAP EPS of -$0.15 misses by $0.12, revenue of $76.2M misses by $6.69M
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Here are the major earnings before the open Monday
Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates
CytomX Therapeutics Target of Unusually Large Options Trading (NASDAQ:CTMX)
Top Quant ranked small cap stocks with negative EPS surprises
CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts
CytomX Therapeutics to Present at Upcoming February Conferences
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of “Moderate Buy” from Brokerages
CytomX Stock Rises 31% in a Month: Here's What You Should Know
CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
CytomX Therapeutics (NASDAQ:CTMX) Reaches New 12-Month High – Still a Buy?
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Rating of “Moderate Buy” by Brokerages
CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages
CytomX Therapeutics to Present at Upcoming December Investor Conferences